Biotech fundraising has a rhythm. Scientific progress and company milestones can happen anytime, but investor attention follows a recognizable calendar shaped by availability, market activity, and major industry conferences.

A recent NFX article, The Seasons of Fundraising, describes the same pattern from an investor’s perspective. Deals can happen throughout the year, but some windows are more active than others:¹

• January through early March: One of the year’s most active periods, beginning with the J.P. Morgan Healthcare Conference for biotech companies.
• After spring break through early June: Fundraising remains active, although the pace is generally quieter than in the first quarter or fall.
• June through August: Deals still move forward, but vacations and changing schedules can make it harder to maintain momentum.
• Labor Day through Thanksgiving: A second short, concentrated fundraising window before activity slows for the holidays.

 
We are now in the active fall season. It will narrow as Thanksgiving approaches, slow through the year-end holidays, and build again around JPM. For biotech companies planning to fundraise, enter partnering discussions, or emerge from stealth, the next window is already close enough to require action.

Your company evolved. Did your materials evolve with it?

Over the past year, your company may have advanced a program, generated new data, refined its development strategy, expanded the team, or established a new partnership. Each development changes what investors need to understand about the company and why its work matters now.

Your communications should reflect that progress. Investors should be able to see what you are developing, the value embedded in the science, the milestones ahead, and the team advancing the work. The website creates the first impression. The presentation carries the narrative into the meeting. Together, they should communicate one current and credible company story.

That work is difficult to complete once fundraising begins. Leadership attention quickly shifts to meetings, scientific questions, diligence requests, and follow-up. Preparing the narrative and essential materials before the next active season gives the team time to make deliberate decisions, rather than treating communications as another urgent task.

Plan now for JPM

Biotech development does not pause for the fundraising calendar. The companies best positioned for JPM will use the months ahead to determine what has changed, what investors need to understand, and whether their core materials support the next business objective.

At Theoria Creative, we help biotech companies identify the business value in their science and build the positioning, narrative, and communications needed for financing and partnering conversations. Fundraising has been especially challenging for newly formed and early-stage biotech companies. They need a credible investor presence that reflects the quality of their science, often before they have the resources for a fully customized engagement. We wanted to find a way to support these companies earlier in their journey.

For the past 16 years, Theoria has worked closely with biotech investors, developing a deep understanding of how they evaluate science, assess opportunities, and make investment decisions. This perspective informs the strategic thinking and creative direction behind our high-stakes investor communications.

By combining investor insight with scientific expertise and new technologies, including AI-supported workflows, we have created a more efficient way to give early-stage biotech companies the essential materials they need to present their science and business opportunity professionally to investors. The result is a focused offering designed for early-stage biotech companies preparing to enter investor and partnering conversations.

The Theoria Biotech Startup Package

The Theoria Biotech Startup Package brings together the foundational materials an early-stage company needs to establish a cohesive presence for investor and partnering conversations:

• A foundational website: A homepage plus About, Team, Pipeline, and Contact pages.
• A PowerPoint template: A consistent, professional format the team can use across presentations.
• A logo: A visual identity that brings the company’s core materials together.

The package gives early-stage biotech companies the essentials without requiring a full custom engagement. Theoria’s biotech experience guides the work, and a template-based process makes the package more affordable for early-stage companies.

Prepare for the next fundraising season

The fall fundraising season is already underway. If JPM is your next target, now is the time to ensure your company materials reflect the quality of your science and the professionalism of your organization.

Tell us about your company and timeline. Contact Theoria Creative to discuss how the Biotech Startup Package can help you prepare for JPM and the next fundraising season.

Request package pricing

Sources

1. NFX: The Seasons of Fundraising